Form 8-K - Current report:
SEC Accession No. 0001213900-20-009372
Filing Date
2020-04-17
Accepted
2020-04-16 18:24:21
Documents
4
Period of Report
2020-04-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea120711-8k_inmunebioinc.htm 8-K 26645
2 AT-THE-MARKET SALES AGREEMENT, DATED APRIL 16, 2020, BETWEEN THE COMPANY AND BTI ea120711ex1-1_inmunebio.htm EX-1.1 254120
3 OPINION OF SICHENZIA ROSS FERENCE LLP ea120711ex5-1_inmunebio.htm EX-5.1 13760
4 GRAPHIC logo.jpg GRAPHIC 8195
  Complete submission text file 0001213900-20-009372.txt   307072
Mailing Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037
Business Address 1200 PROSPECT STREET SUITE 525 LA JOLLA CA 92037 8589643720
Inmune Bio, Inc. (Filer) CIK: 0001711754 (see all company filings)

EIN.: 475205835 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38793 | Film No.: 20797348
SIC: 2836 Biological Products, (No Diagnostic Substances)